PO.MCB07.03 · 分子与细胞生物学

利用TempO-LINC实现对RNA降解和低起始量样本的单细胞转录组分析

Enabling single-cell transcriptomics from samples with degraded and low-input RNA using TempO-LINC

海报缩略图:利用TempO-LINC实现对RNA降解和低起始量样本的单细胞转录组分析
编号 5954 展板 9 时间 4/21 02:00–05:00 区域 Section 22 主讲 Zhoutao (Tom) Chen, PhD
分会场 Mechanisms and Dynamics of Gene Expression
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Kevin White1, Albus Kilili2, Hanna Ha2, Dennis Eastburn1, Nathan Jayne1, Salvatore Camiolo2, Zhoutao Chen1, Bruce Seligmann1

1BioSpyder Technologies, Inc., Carlsbad, CA,2BioClavis, LTD, Glasgow, United Kingdom

摘要 Abstract

中文摘要
背景:单细胞RNA测序(scRNA-seq)技术能够表征细胞异质性和稀有细胞类型,并绘制复杂组织中的细胞状态。然而,scRNA-seq在临床样本中的表现受限于RNA降解、片段化或本身较低的RNA丰度。外周血单个核细胞(PBMC)是一种常见的低RNA、异质性样本,而福尔马林固定石蜡包埋(FFPE)组织作为人类样本的宝贵档案,由于组织处理常含有质量/数量欠佳的降解RNA。因此,TempO-LINC作为一种靶向、无需仪器的单细胞转录组检测,被设计用于对低RNA完整性具有强耐受性的高通量基因表达分析。在此,我们报告TempO-LINC能够在人类PBMC以及来自人和小鼠的解离FFPE组织中实现稳健的基因表达分析和稀有细胞亚型检测。 方法:TempO-LINC检测是一种可扩展的组合式拆分-合并(split-pool)条形码方法,用于在固定细胞/细胞核中对RNA分子进行独特索引。来自三名供者的冷冻保存PBMC使用TempO-LINC固定试剂盒固定,并用TempO-Seq人全转录组v2.1探针组进行分析。来自人肺和小鼠脑的FFPE蜡块被切片,每块两张30µm厚切片,经脱蜡、酶解离、过滤,然后用TempO-LINC固定试剂盒处理。分别使用人全转录组v2.1和小鼠全转录组v1.1探针组对FFPE肺和脑进行TempO-LINC scRNA-seq。数据处理和可视化使用开源的Python Scanpy和R Bioconductor软件包完成。 结果:对12,027个PBMC的分析揭示了16个转录上不同的细胞群体,包括主要类别的血液/免疫细胞亚群,以及更稀有的造血干/祖细胞和增殖性CD4+ T细胞群体,展示了在低RNA情境下的高灵敏度。TempO-LINC成功生成了FFPE单细胞表达谱,平均比对率为71–93%,每个细胞检测到约1,000个基因。UMAP数据显示来自解离FFPE肺和脑组织的清晰界定的细胞亚型。 结论:TempO-LINC scRNA-seq检测能够跨异质性、低RNA的PBMC和FFPE样本实现高分辨率基因表达分析。这些结果凸显了该检测在从RNA降解样本中确定稀有细胞类型方面的高灵敏度。将TempO-LINC scRNA-seq应用于FFPE标本,为精准医学、生物标志物发现和机制毒理学开辟了新机遇。
查看英文原文 English abstract
Background: Single-cell RNA sequencing (scRNA-seq) technologies enable characterization of cellular heterogeneity and rare cell types, and mapping of cell states in complex tissues. However, scRNA-seq performance in clinical samples is limited by RNA degradation, fragmentation, or inherently low RNA abundance. Peripheral blood mononuclear cells (PBMCs) are a common low RNA, heterogeneous sample, while formalin-fixed paraffin-embedded (FFPE) tissues, an invaluable archive of human samples, often contain degraded RNA of poor quality/quantity, due to tissue processing. Thus, TempO-LINC, a targeted, instrument-free single-cell transcriptomics assay, was designed for high-throughput gene expression profiling with strong tolerance to low RNA integrity. Here, we report that TempO-LINC enables robust gene expression profiling and rare cell subtype detection in human PBMCs and dissociated FFPE tissues from human and mouse. Methods: The TempO-LINC assay is a scalable, combinatorial split-pool barcoding approach to uniquely index RNA molecules in fixed cells/nuclei. Cryopreserved PBMCs from three donors were fixed using the TempO-LINC Fixation Kit and profiled with the TempO-Seq human whole transcriptome v2.1 probe set. FFPE blocks from human lung and mouse brain were sectioned, two 30µm thick sections per block, deparaffinized, enzymatically dissociated, filtered, and then processed with the TempO-LINC Fixation Kit. TempO-LINC scRNA-seq was performed on FFPE lung and brain using the human whole transcriptome v2.1 and mouse whole transcriptome v1.1 probe sets, respectively. Data processing and visualization were performed using the open-source Python Scanpy and R Bioconductor packages. Results: Analysis of 12,027 PBMCs revealed 16 transcriptionally distinct cell populations, including major classes of blood/immune cell subsets, and rarer cell populations of hematopoietic stem/progenitor cells and proliferating CD4+ T cells, demonstrating high sensitivity in low-RNA contexts. TempO-LINC successfully generated FFPE single-cell expression profiles with mean mapping rates from 71-93% and ~1,000 genes detected per cell. UMAP data shows clearly defined cell subtypes from dissociated FFPE lung and brain tissues. Conclusion : The TempO-LINC scRNA-seq assay enables high-resolution gene expression profiling across heterogenous, low-RNA PBMCs and FFPE samples. These results highlight the assay's high sensitivity in determining rare cell types from samples with degraded RNA. Applying TempO-LINC scRNA-seq on FFPE specimens unlocks new opportunities in precision medicine, biomarker discovery, and mechanistic toxicology.
利益披露 Disclosure
K. White, BioSpyder Technologies Employment. A. Kilili, BioClavis, Ltd Employment. H. Ha, BioClavis ltd Employment. D. Eastburn, Biospyder technologies Employment. N. Jayne, Biospyder Employment. S. Camiolo, Bioclavis Employment. Z. Chen, Biospyder Employment. B. Seligmann, Biospyder Employment, Stock.

← 返回 AACR 2026 检索